Bleomycin
Definition
Bleomycin (Blenoxane) kills cancer cells by damaging the genetic material known as DNA, thus preventing cells from repairing themselves.
Purpose
Bleomycin is used in the treatment of a number of different cancers, including cancer of the head and neck, skin, esophagus, lung, testis, penis, vulva, cervix, and genitourinary tract. In addition, it is used in the treatment of Hodgkin's disease and non-Hodgkin's lymphomas. It may also be used to treat Kaposi's sarcoma.
Because bleomycin is used in the treatment of so many different cancers, only a sampling of its uses can be provided here. In the treatment of Hodgkin's disease, one chemotherapy regimen used is the so-called ABVD, which consists of doxorubicin, bleomycin, vinblastine, and dacarbazine. Another regimen is called MOPP/ABV, which consists of mechlorethamine, vincristine, prednisone, procarbazine, doxorubicin, bleomycin, and vinblastine.
A treatment used for stage III and IV non-Hodgkin's lymphoma is the CHOP-bleomycin regimen, which consists of cyclophosphamide, hydroxydaunomycin, vincristine, prednisone, and bleomycin. Another approach to the same illness involves the m-BACOD chemotherapy regimen, which consists of methotrexate, bleomycin, doxorubicin,
Description
Bleomycin is an antitumor antibiotic that fights cancer by attacking the DNA in cancerous cells, thus interfering with cell growth.
Recommended dosage
A dose of 0.25-0.50 units/kg (10-20 units per square meter) is given once or twice a week either intravenously, intramuscularly, or subcutaneously. A small test dose should be given first to test for a possible severe allergic reaction.
Precautions
Patients who receive certain forms of oxygen therapy while taking bleomycin or who receive anesthesia while taking bleomycin are at increased risk for developing serious lung problems.
Patients given bleomycin may develop an acute allergic reaction that may be fatal in rare cases. Therefore, a patient should only receive a small test dose of bleomycin the first time the drug is administered. After this initial dose the patient is observed carefully for one hour. Assuming no further problems appear, the patient may then receive a standard dose.
The likelihood that lung damage will occur increases if a patient receives more than 450-500 units of the drug during an entire lifetime. So, it is prudent to limit the amount of this medication given. Furthermore, it may be unwise to give bleomycin in regimens containing cyclophosphamide, as this combination also increases the likelihood that lung damage will occur.
